Sireesh Appajosyula - 08 Oct 2024 Form 4/A - Amendment Insider Report for Tharimmune, Inc. (THAR)

Role
Chief Operating Officer, Director
Signature
/s/ Randy Milby as Attorney-In-Fact for Sireesh Appajosyula
Issuer symbol
THAR
Transactions as of
08 Oct 2024
Net transactions value
+$9,650
Form type
4/A - Amendment
Filing time
09 Oct 2024, 09:58:52 UTC
Date Of Original Report
08 Oct 2024
Previous filing
08 Oct 2024
Next filing
13 Nov 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction THAR Common Stock Purchase $9,650 +5,000 +660% $1.93 5,758 08 Oct 2024 Direct
holding THAR Common Stock 2,593 08 Oct 2024 See footnote F1
holding THAR Common Stock 21 08 Oct 2024 See footnote F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 2,593 shares of common stock are held indirectly by Highpoint Pharmaceuticals, LLC and 21 shares of common stock are held by Channel BioConsulting LLC. The Reporting Person is the managing member of each of Highpoint Pharmaceuticals, LLC and Channel BioConsulting LLC and in such capacity has the right to vote and dispose of the securities held by such entities.